PI3Kγδ抑制剂联合放疗增强PD-1阻断在乳腺癌模型中的抗肿瘤免疫效果
该研究在免疫健全与缺陷小鼠乳腺癌模型及人源化患者来源异种移植模型中,探讨PI3Kγδ抑制剂联合放疗与PD-1阻断的疗效。三联疗法显著延缓原发肿瘤生长、增强远隔效应并改善生存,且降低免疫抑制细胞比例、增加CD8+ T细胞。TCGA队列分析显示高Treg/CD8+与M2/M1 TAM比值与总生存差相关。
要点
- PI3Kγδ抑制剂联合RT与PD-1阻断显著延缓肿瘤生长并改善生存。
- 三联疗法降低Treg、MDSC和M2 TAM比例,增加CD8+ T细胞。
- 人源化PDX模型中三联疗法显著延缓肿瘤生长并下调免疫抑制通路。
核心结论
- PI3Kγ和PI3Kδ是免疫抑制性肿瘤微环境中的临床相关靶点,三联疗法可能克服免疫冷肿瘤的治疗抵抗。
研究设计与样本
- 研究使用4T1小鼠乳腺癌细胞在免疫健全与缺陷BALB/c小鼠中种植,肿瘤接受3次24 Gy放疗,随后隔日给予PD-1阻断和PI3Kγδ抑制剂持续2周。
- 相同实验在人源化患者来源乳腺癌异种移植模型中进行,并对肿瘤测序以鉴定免疫相关通路和浸润免疫细胞。
- 从TCGA泛癌队列获取转录组和临床数据,使用去卷积算法分析免疫细胞组成。
主要发现
- PI3Kγδ抑制剂联合放疗和PD-1阻断显著延缓原发肿瘤生长、增强远隔效应并改善动物生存。
- 放疗显著增加CD8+细胞毒性T细胞、免疫抑制性Treg、髓源性抑制细胞和M2肿瘤相关巨噬细胞比例。
- PI3Kγδ抑制剂显著降低Treg、髓源性抑制细胞和M2 TAM比例,三联治疗后脾、淋巴结和肿瘤中CD8+ T细胞群大幅增加。
- 人源化PDX模型中三联疗法显著延缓肿瘤生长并减少免疫抑制通路。
- TCGA队列中高Treg/CD8+ T细胞比值和高M2/M1 TAM比值与患者总生存差相关。
临床怎么用
- PI3Kγδ抑制剂联合放疗和PD-1阻断可能作为克服免疫冷肿瘤治疗抵抗的临床策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We hypothesised that the combined use of radiation therapy and a phosphoinositide 3-kinaseγδ inhibitor to reduce immune suppression would enhance the efficacy of an immune checkpoint inhibitor. METHODS: Murine breast cancer cells (4T1) were grown in both immune-competent and -deficient BALB/c mice, and tumours were irradiated by 3 fractions of 24 Gy. A PD-1 blockade and a phosphoinositide 3-kinase (PI3K)γδ inhibitor were then administered every other day for 2 weeks. The same experiments were performed in humanised patient-derived breast cancer xenograft model and its tumour was sequenced to identify immune-related pathways and profile infiltrated immune cells. Transcriptomic and clinical data were acquired from The Cancer Genome Atlas pan-cancer cohort, and the deconvolution algorithm was used to profile immune cell repertoire. RESULTS: Using a PI3Kγδ inhibitor, radiation therapy (RT) and PD-1 blockade significantly delayed primary tumour growth, boosted the abscopal effect and improved animal survival. RT significantly increased CD8+cytotoxic T-cell fractions, immune-suppressive regulatory T cells (Tregs), myeloid-derived suppressor cells and M2 tumour-associated macrophages (TAMs). However, the PI3Kγδ inhibitor significantly lowered the proportions of Tregs, myeloid-derived suppressor cells and M2 TAMs, achieving dramatic gains in splenic, nodal, and tumour CD8+ T-cell populations after triple combination therapy. In a humanised patient-derived breast cancer xenograft model, triple combination therapy significantly delayed tumour growth and decreased immune-suppressive pathways. In The Cancer Genome Atlas cohort, high Treg/CD8+ T cell and M2/M1 TAM ratios were associated with poor overall patient survival. CONCLUSION: These findings indicate PI3Kγ and PI3Kδ are clinically relevant targets in an immunosuppressive TME, and combining PI3Kγδ inhibitor, RT and PD-1 blockade may overcome the therapeutic resistance of immunologically cold tumours. SYNOPSIS: Combining PI3Kγδ inhibitor, RT, and PD-1 blockade may be a viable clinical approach, helping to overcome the therapeutic resistance of immunologically cold tumours such as breast cancer.
引用
- Han MG, Jang BS, Kang MH, et al. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model. Eur J Cancer. 2021. PMID: 34601286. doi:10.1016/j.ejca.2021.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。